Sanoculis
Minimally Invasive Surgical Device for Glaucoma Treatment
Startup C Health Tech & Life Sciences Est. 2012
Total Raised
$18.5M
C
Last Round
$14M
3 rounds
Investors
6
4 public
Team
4
1-10 employees
Confidence
99/100
News
7
articles
Patents
1
About
Sanoculis offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. In the course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure. MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerostomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications. In March 2017, Sanoculis was granted CE marking for its MIMS device and procedure.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Core Technology
SensingLaser
Target Customer
Healthcare & Life SciencesHealthcareProviders
Business Model
B2B
Tags
minimally-invasivesurgeryglaucomahospitalssurgeonsophthalmologymedical-deviceshealthcare-providerseye-diseasesclinicstreatments
Funding & Events
Sep 2019
B Round $3.5M
HCS Capital , BIOLIGHT Life Sciences
Jul 2022
C Round $14M
Bausch + Lomb, Eckuity, Infinity Group
Aug 2016
A Round $1M
Zohar Zisapel (Late)
News (7)
Apr 17, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Product Stage
Apr 17, 2025 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Sanoculis Ltd., a company specializing in ophthalmic medical device technologies, today announced that it has received CE Mark approval under...
Product Stage
Jan 25, 2023 · www.prnewswire.com
Growth-Positive
Eckuity Joins Bausch + Lomb in an Equity Investment in Sanoculis
InvestmentPartnersAcquisition
Jul 28, 2022 · www.prnewswire.com
growth-positive
Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma
InvestmentPartners
Mar 21, 2017 · eyewire.news
Neutral
News - Eyewire+
Aug 25, 2016 · www.globes.co.il
growth-positive
Alfred Mann's legacy stimulates Israeli innovation
InvestmentExpand
May 10, 2016 · www.healio.com
growth-positive
Minimally invasive micro sclerostomy may be alternative to trabeculectomy
Customers
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
9
District
Center District
Founded
2012
Registrar
514733724
Crunchbase
sanoculis
Locations
Landau Street 10, Kiryat Ono, Israel
Links
Website
LinkedIn
Admin
Last Update
May 14, 2025
Verified by
Natalia Golczar
Claimed
Yes
Missing
markets
Team (4)
Nir Israeli
Co-founder & CEO
Founder
Vadim Shmukler
Co-founder & CTO
Founder
Dr. Yoseph Glovinsky
Co-founder & Medical Director
Founder
Elad Shalev
VP of Global Marketing & Sales